Chatham House - Radical new business model for pharmaceutical industry needed to avert antibiotic resistance crisis
Revenues for pharmaceutical companies need to be 'delinked' from sales of antibiotics to avoid their over-use and avert a public health crisis, says a new report from the think-tank Chatham House.
Over-use of antibiotics is contributing to the growing resistance of potentially deadly bacteria to existing drugs, threatening a public health crisis in the near future. The report notes that, by 2050, failing to tackle antibiotic resistance could result in 10 million premature deaths per year.
Novel antibiotics to combat resistant pathogens are thus desperately needed, but market incentives are exacerbating the problem.
'The current business model requires high levels of antibiotic use in order to recover the costs of R&D. But mitigating the spread of resistance demands just the opposite: restrictions on the use of antibiotics.'
To tackle this catch-22 problem, the Centre on Global Health Security at Chatham House recommends the establishment of a global body to implement a radical new business model for the industry, which would encourage investment and promote global access to - and conservation of - antibiotics.
The current business model has several perverse effects. As R&D is an inherently risky and costly endeavour, the industry is chronically under-investing in new treatments. Today, few large pharmaceutical companies retain active antibacterial drug discovery programmes. Re-stoking the industry's interest in antibiotics would be one of the primary roles of the new body.
Secondly, the need to recover sunk cost under the current business model encourages both high prices and over-marketing of successful drugs, making potentially life-saving treatments unaffordable to many in developing countries, while simultaneously encouraging over-use in developed markets and increasing resistance.
The new global body would address these challenges by ‘delinking’ pharmaceutical revenues from sales of antibiotics. It would do this by directly financing the research and development of new drugs, which it would then acquire at a price based on production costs rather than the recovery of R&D expenses. Acquisition could take the form of procurement contracts with companies, the purchase of full IP rights or other licensing mechanisms.
This would enable it to promote global access to antibiotics while simultaneously restricting over-use. Conservation would be promoted through education, regulation and good clinical practice, with the report recommending that 'proven conservation methods such as antibiotic stewardship programmes… be incentivized and implemented immediately.'
Priorities for R&D financing would be based on a comprehensive assessment of threats arising from resistance. Antibiotics would qualify for the highest level of financial incentives if they combat resistant pathogens posing a serious threat to human health.
Finance for the new body would come from individual nation states, with the report noting that this could 'begin with a core group of countries with significant research activity and large antibiotic markets, (though) it is envisaged that all high income countries should make an appropriate financial contribution.'
It is not yet clear exactly how much funding would be necessary to combat resistance, but with inaction expected to cost $100 trillion in cumulative economic damage, the report argues that 'an additional global investment of up to $3.5 billion a year (about 10 per cent of the current value of global sales of antibiotics) would be a bargain.'
Towards a New Global Business Model for Antibiotics: Delinking Revenues from Sales, is a Chatham House report edited by Charles Clift, Unni Gopinathan, Chantal Morel, Kevin Outterson, John-Arne Røttingen and Anthony So.
For more information, or to request an interview with the editors, contact the press office.
Latest News from
Civitas - Anti-racism industry creating a dependency upon race experts in which ‘racial divisions are becoming ever more firmly entrenched’, says think-tank report08/04/2021 10:35:00
The anti-racism industry ‘creates a dependency’ upon a race discourse that sows division, finds a new Civitas report. ‘The tragic consequence’, the report finds, ‘is that racial divisions are becoming ever more firmly entrenched’.
The King’s Fund response to The Commission on Race and Ethnic Disparities report02/04/2021 09:10:00
Richard Murray, Chief Executive of The King’s Fund, commented on the report of the Commission on Race and Ethnic Disparities
UK economy will likely bounce back “more strongly than many expect,” says IEA expert01/04/2021 14:35:00
Julian Jessop, Economics Fellow at the free market think tank the Institute of Economic Affairs, responded to the latest GDP data from the Office for National Statistics
Civitas - ‘Nurturing Britain’s high-tech capabilities’ and ‘safeguarding critical industries’ should be central to managing potential risks of economic dependence on China, think-tank report finds01/04/2021 13:35:00
‘British policymakers should think carefully about the degree of economic reliance on China that it is wise to tolerate where critical infrastructure is concerned’, a new think-tank paper suggests.
Commit to new deal for healthcare workers or risk ‘deadly exodus’, IPPR warns government01/04/2021 12:35:00
As many as one in four healthcare workers – equivalent to 330,000 staff - say they are more likely to leave the NHS due to a year of unprecedented pressure, according to new polling by IPPR/YouGov. The figure - which includes the equivalent of 100,000 nurses and 8,000 midwives – adds pressure to a workforce that was experiencing a crisis of unfilled vacancies even before the pandemic.
UK right to call for WTO reform, says IEA expert01/04/2021 11:35:00
Mark Littlewood, Director General at free market think tank the Institute of Economic Affairs, responded to the news that Britain it to use its G7 presidency to press for reform of the World Trade Organization (WTO)
IFS - Scottish Government funding per person is over 30% higher than equivalent English funding. But it has still chosen to use temporary COVID funding to pay for some new permanent spending commitments.01/04/2021 10:35:00
Real-terms funding for the Scottish Government’s day-to-day (or resource) spending in 2021-22 is still set to be 2% lower per person than in 2010-11, after excluding temporary COVID-19 related funding, and adjusting for new responsibilities.
Financial Ombudsman Service needs “major reform,” says new research01/04/2021 09:35:00
A new report from the Institute of Economic Affairs, written by IEA Head of Regulatory Affairs Victoria Hewson, draws attention to the shortcomings of the Financial Ombudsman Service (FOS).